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Abstract
Multiple sclerosis, the most common neurologic disorder of young adults, is traditionally
considered to be an inflammatory, autoimmune, demyelinating disease of the central nervous
system. Based on this understanding, the initial therapeutic strategies were directed at immune
modulation and inflammation control. These approaches, including high-dose corticosteroids for
acute relapses and long-term use of parenteral interferon-β, glatiramer acetate or natalizumab for
disease modification, are at best moderately effective. Growing evidence supports that, while an
inflammatory pathology characterizes the early relapsing stage of multiple sclerosis,
neurodegenerative pathology dominates the later progressive stage of the disease. Multiple
sclerosis disease-modifying therapies currently in development attempt to specifically target the
underlying pathology at each stage of the disease, while avoiding frequent self-injection. These
include a variety of oral medications and monoclonal antibodies to reduce inflammation in relapsing
multiple sclerosis and agents intended to promote neuroprotection and neurorepair in progressive
multiple sclerosis. Although newer therapies for relapsing MS have the potential to be more
effective and easier to administer than current therapies, they also carry greater risks. Effective
treatments for progressive multiple sclerosis are still being sought.
Introduction
Multiple sclerosis (MS) is a chronic progressive disorder of
the central nervous system (CNS). It is traditionally con-
sidered to be an inflammatory disorder characterized by
episodic CNS demyelination. However, current under-
standing is that neurodegeneration dominates the pro-
gressive stages of the disease. This article summarizes the
pathogenesis of MS, reviews approved MS therapies and
discusses the proposed mechanisms and likely benefits
and risks of new MS therapeutics.
Disease pathogenesis and disease subtypes
MS presents in most people (80%) with clinical relapses
characterized by fully or partially-reversible focal neuro-
logical deficits [1]. Relapsing-remitting MS (RRMS) is
dominated by inflammation, oedema and the physiologic
actions of cytokines [2]. Active inflammation of the brain
and spinal cord is visualized as gadolinium enhancing
white matter lesions on magnetic resonance imaging
(MRI). After 10-20 years, or median age 39.1 years, about
half of those with RRMS gradually accumulate irreversible
neurologic deficits in the absence of clinical relapses or
new white matter lesions by MRI [3]. This stage is known
as secondary progressive MS (SPMS). The remaining 20%
with progressive clinical deterioration from the onset of
the disease have primary progressive MS (PPMS) [1].
PPMS and SPMS are thought to be dominated by axonal
degeneration in the absence of overt inflammation [4]
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increased susceptibility to injury caused by the loss of the
myelin sheath.
Current MS therapeutics
Clinically significant acute MS relapses are usually treated
with high-dose, short-term, intravenous corticosteroids
(methylprednisolone 1 g/day for 3-5 days). This shortens
relapse duration but does not improve the degree of
recovery or the long-term course of the disease [5-7]. Dis-
ease-modifying therapies (DMT) for MS alter the course of
the disease. They lower the clinical relapse rate, extend the
time to next relapse and reduce the accumulation of new
lesions on MRI, all of which are intended to decrease the
long-term accumulation of disability. The first approved
DMT for MS, subcutaneous interferon beta-1b (IFNβ-1b,
marketed as Betaseron in the USA and as Betaferon in
Europe), was approved by the US Food and Drug Admin-
istration (FDA) for RRMS in 1993. This was based on the
pivotal placebo-controlled trial in which treated subjects
had significantly lower annualised relapse rates and more
subjects were relapse-free after 2 years [8]. IFNβ (inter-
feron beta) acts as an anti-inflammatory and has several
mechanisms of action, including a reduction in the pro-
duction of pro-inflammatory IFNγ and TNFα, inhibition
of T-cell activation and clonal expansion, modulation of
cytokine and matrix metalloproteinase production and
the release and inhibition of T-cell migration and entry
into the CNS [9].
Since the release of IFNβ-1b, five other parenteral medica-
tions have been approved for the treatment of MS: IFNβ-
1a (Avonex©, Biogen Idec, North Carolina, USA), IFNβ-1a
(Rebif©, EMD Serono, Geneva, Switzerland), glatiramer
acetate (GA, Copaxone©, Teva Pharmaceuticals, Petah
Tikva, Israel), mitoxantrone (Novantrone©, OSI Pharma-
ceuticals, New York, USA) and natalizumab (Tysabri©,
Biogen Idec, Massachusetts, USA). The IFN products are
thought to all have similar mechanisms of action
although they differ in the route of administration, rapid-
ity of onset of action and risk of induction of neutralizing
antibodies [10]. In contrast, GA - a synthetic copolymer of
glutamic acid, lysine, alanine and tyrosine - is believed to
activate Th2 regulatory cells in the periphery. These acti-
vated Th2 cells cross the blood brain barrier (BBB) and
enter the CNS where they shift the immune response from
pro-inflammatory to anti-inflammatory by secreting
cytokines that down-regulate the inflammatory response
and inhibit pro-inflammatory Th1 cells. Mitoxantrone is
an antineoplastic agent that inhibits DNA and RNA syn-
thesis of B and T-cells. While approved for the treatment
of RRMS and SPMS [11-13], it has only shown a clear ben-
efit for patients still experiencing relapses and developing
new MRI lesions. Increasing recognition of short and
long-term risks of cardiotoxicity, acute leukaemia and
bone marrow suppression limit its use [14-16]. Natalizu-
mab is the first monoclonal antibody (MAB) therapy
approved for the treatment of MS. It binds to VLA-4 on the
surface of leukocytes, preventing T-cells from crossing the
BBB into the CNS [17]. Natalizumab was found to reduce
MS relapses by 68% compared to placebo[18] but its use
is limited by its association with the development of pro-
gressive multifocal leukoencephalopathy (24 patients at
the time of this writing)[19], as well as melanoma[20]and
primary CNS lymphoma[21] which are all probably due
to an altered immune surveillance. In response, the FDA
limited approval of natalizumab to patients failing other
MS therapies and requires patients to be enrolled in a
safety monitoring programme.
Future directions
DMT development for MS is an area of active research and
many potential agents are in various phases of investiga-
tion. Most of these are oral medications or MABs that tar-
get specific aspects of inflammation in RRMS. Others are
designed to have neuroprotective and neurorestorative
effects in PPMS and SPMS (Figure 1).
Oral anti-inflammatory agents for RRMS (Table 1)
Fingolimod (FTY720), a small molecule derived from a
fungus and chemically related to sphingosine, causes
internalization of sphingosine-1-phosphate (S1P) recep-
tors on lymphocytes, thereby blocking their egress from
lymph nodes and thymus. The reversible lymphocytopae-
Disease-modifying therapies in development target the pathology underlying the stage of multipl  sclerosis (MS)Figure 1
Disease-modifying therapies in development target 
the pathology underlying the stage of multiple sclero-
sis (MS). Clinical course is indicated by the black line with 
stepwise increases in disability in early disease caused by 
relapses and, later, by gradual progression of disability in sec-
ondary progressive MS (SPMS) and from disease onset in pri-
mary progressive MS (PPMS). Anti-inflammatory therapies 
are effective in relapsing-remitting MS and SPMS when 
relapses are still present. Neuroprotective therapies target 
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causing inflammation [22]. Fingolimod may also have
direct effects via the S1P receptors present on all CNS cells
types. A phase II clinical trial in RRMS found that fingoli-
mod significantly reduced gadolinium-enhancing lesions
and relapse rates compared to placebo [23] and a second
trial demonstrated fingolimod's superiority to IFNβ-1a
[24]. A European phase III clinical trial of fingolimod for
RRMS has been completed, and a USA phase III trial is
underway http://www.clinicaltrials.gov. Frequent adverse
events associated with fingolimod include nasopharyngi-
tis, dyspnea, headache and nausea. Rare serious adverse
events in the trials were skin cancers and two deaths, one
each from herpes encephalitis and disseminated varicella,
all suggesting an inadequate immune surveillance.
The antimetabolite cladribine, an adenosine analogue,
incorporates into DNA and causes the death of rapidly
proliferating inflammatory B and T cells, thus resulting in
selective and long-lasting lymphocyte depletion.
Approved as a therapy for use in hairy-cell leukaemia,
early trials indicated that cladribine was effective for
RRMS but not SPMS [25,26]. A recent phase III trial in
RRMS (CLARITY) demonstrated a significant benefit of
cladribine over placebo with a reduction in annualized
relapse rate of over 50% at 96 weeks [27]. Based on this
trial, the manufacturers are applying for FDA registration
for cladribine. Cladribine has an appealing short admin-
istration schedule and is generally well-tolerated, but
there were some serious adverse events in the trial includ-
ing herpes zoster in 2% of subjects, three cancers and four
deaths in the cladribine groups [27].
There are three oral agents in phase III trials in RRMS,
laquinimod, teriflunomide and BG00012. Laquinimode
and teriflunomide are thought to work in part by shifting
the T-cell balance from pro-inflammatory Th1 cells to
anti-inflammatory Th2 cells. Laquinimod is a chemically
and pharmacologically distinct derivative of the drug
roquinimex, the study of which in RRMS was halted due
to significant pulmonary and cardiac toxicity [28]. A 24
week phase II trial of laquinimod demonstrated a signifi-
cant reduction of gadolinium-enhancing lesions on MRI
over placebo [29]. Based on these promising early results,
two phase III trials are underway in patients with RRMS.
Teriflunomide is the active metabolite of leflunomide, a
drug used in rheumatoid arthritis. It also inhibits dihydro-
orotate dehydrogenase, the enzyme necessary for de novo
synthesis of pyrimidine, thus reducing activated B and T
cell proliferation [30]. A promising phase II trial [31] has
led to phase III placebo-controlled trials of teriflunomide
RRMS and clinically isolated syndrome (CIS). Need for
pre-treatment with cholestyramine or activated charcoal
and the frequent association of hypertension, alopecia
and rash could potentially limit its use. BG00012 proba-
bly affects MS primarily through its anti-oxidant effects. It
is an oral formulation of dimethyl fumarate, a topical
agent used to treat psoriasis. Promising early studies [32]
led to a phase III trial now underway.
Based on the observation that there is a reduction in MS
relapses during pregnancy, a condition associated with
high levels of and progesterone, it is thought that or pro-
gesterone may benefit patients with MS and progesterone
have potent anti-inflammatory effects and may also pro-
vide neuroprotective benefits by increasing oligodendro-
cyte precursor cell number[33] and promoting
oligodendrocyte process formation [34]. Phase III trials of
oral estriol in conjunction with glatiramer acetate in
RRMS are ongoing.
Monoclonal antibodies for RRMS (Table 2)
Alemtuzumab targets the CD52 antigen present on T cells,
B cells, monocytes, macrophages and eosinophils, but not
stem cells, and causes reversible leukocyte depletion. Ale-
mtuzumab is approved for chronic lymphocytic leukae-
mia and showed promise in early trials for RRMS [35] but
not SPMS [36]. Patients with RRMS treated with alemtu-
zumab compared to IFNβ-1a had significantly lower risk
for relapse (75%) and reduction in sustained disability
(65%) over 2 years [35]. Safety concerns included three
cases of immune thrombocytopenic purpura with one
fatality, Grave's disease, autoimmune anaemias and neu-
tropenias and Guillain-Barre syndrome. Phase III trials are
ongoing. Daclizumab depletes leukocytes by binding to
the α-chain of the IL-2 receptor (CD25) required for T cell
Table 1: Oral anti-inflammatory agents for relapsing-remitting multiple sclerosis (RRMS).
Agent Proposed mechanisms of action Stage of development*
Fingolimod (FTY 720) Binds sphingosine-1-phosphate on T cells preventing circulation and CNS entry Phase III for RRMS
Cladribine Selectively depletes B and T cells by causing DNA damage Phase III for RRMS and CIS
Laquinimod Shifts T cells from TH1 (pro-inflammatory) to TH2 (anti-inflammatory) Phase III
Teriflunomide Shifts T cells from TH1 (pro-inflammatory) to TH2 (anti-inflammatory); Blocks 
pyrimidine and reproduction of rapidly dividing B and T cells
Phase III for RRMS and CIS
BG00012 (dimethyl fumarate) Antioxidant Phase III
*compiled from clinicaltrials.gov
CIS, clinically isolated syndrome; CNS, central nervous systemPage 3 of 6
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treatment of renal transplant rejection, appears to stabi-
lize disease in RRMS patients who have failed IFN therapy
[37,38] and is in Phase II clinical trials for RRMS. Adverse
events associated with daclizumab include thromboses,
lymphoproliferative disorders, and infections. Rituximab,
a MAB that depletes CD20+ B cells, is an approved therapy
for haematological malignancies, rheumatoid arthritis
and thrombocytopenic purpura. B-cell dependent mecha-
nisms such as antigen presentation, antibody secretion
and demyelination, are increasingly implicated in the
pathogenesis of MS [39,40]. A phase II trial [41] and case
reports [42] show promise for its use in RRMS [43].
Adverse effects of rituximab include progressive multifo-
cal leukoencephalopathy, pancytopenias, Stevens-John-
son syndrome and rare infections.
Neuroprotective and neurorestorative agents for PPMS 
and SPMS
Thus far, all of the anti-inflammatory therapies that are
effective in RRMS have had minimal or no effect in con-
trolling progressive MS. There is a growing belief that
SPMS and PPMS will not respond to anti-inflammatory
therapies and that neuroprotective and neurorestorative
therapies that affect neuronal integrity will be required for
progressive MS. A variety of existing and novel approaches
are under investigation as neuroprotective and neu-
rorestorative therapies in progressive as well as relapsing
MS (Table 3). Therapeutic strategies include protecting
demyelinated axons as well as oligodendrocytes (the CNS
myelin-producing cells) from oxidative injury, promoting
neuronal remyelination and restoring neuronal growth
and function with neurotrophic factors [44]. Lipoic acid,
a fatty acid present in certain foods and available as an
oral supplement, may protect oligodendrocytes by anti-
oxidant mechanisms and effects on microglia. Lipoic acid
is well tolerated [45] and phase II trials of this compound
in RRMS and SPMS are being planned. Drugs that block
glutamate receptors present on demyelinated axons may
prevent oxidative injury [46]. Riluzole, an oral glutamate
NMDA receptor antagonist approved for use in amyo-
trophic lateral sclerosis [47], is being evaluated in con-
junction with IFNβ-1a in a phase II trial for early MS.
Another strategy for neuroprotection in MS is selective
sodium channel blockade with antiepileptic medications
including phenytoin, topiramate and lamotrigine [48,49].
Table 2: Monoclonal antibodies for relapsing-remitting multiple sclerosis (RRMS)
Agent Proposed mechanisms of action Stage of development*
Alemtuzamab Leukocyte depletion; Depletes CD52 B and T cell populations, monocytes, macrophages and 
eosinophils
Phase III for RRMS
Daclizumab Leukocyte depletion; Binds cell-surface receptor IL2; reduces T cell proliferation and activation Phase II for RRMS
Rituximab B cell-directed therapy; Depletes CD20 B cell population Phase III for RRMS
*Compiled from http://www.clinicaltrials.gov
Table 3: Oral and parenteral neuroprotective and neurorestorative agents for primary progressive multiple sclerosis (MS) and 
secondary progressive MS.
Strategy Drug class Agents *
Protection of oligodendrocytes/axons from oxidative injury Antioxidants Lipoic acid









Promotion of remyelination Stem cells Embryonic, autologous
LINGO-1 Anti-LINGO-1 antibodies
Pregnancy hormones Estriol
Neurotrophic factors to help restore neuronal function Neurotrophic factors
Glial-derived: GDNF, IGF, CNTF, neurturin, artemin, persephin
AMPA/Kainate: NGF, BDNF, NT3/4
*oral agents are indicated in italics
AMPA, α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate; BDNF, brain-derived neurotrophic factor; CNTF, ciliary neurotrophic factor; GDNF, 
glial cell line-derived neurotrophic factor; GYKI-52466, a 2, 3-benzodiazepine; IGF, insulin-like growth factor; LINGO-1, leucine rich repeat and Ig 
domain-containing, Nogo Receptor-interacting protein 1; NBXX, 2, 3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione; NMDA, N-
methyl-D-aspartic acid; NGF, nerve growth factor; NT3/4, neurotrophin 3 and 4.Page 4 of 6
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failed to meet its primary endpoint of reducing the rate of
central cerebral volume loss [50,51].
Trials of stem cell transplantation, with the goal of repop-
ulating oligodendrocytes, are underway in people with
MS. Remyelination may also be promoted by blocking
leucine rich repeat and Ig domain-containing, Nogo
Receptor-interacting protein 1 (LINGO-1), a protein on
the surface of neurons that inhibits differentiation of pre-
cursor oligodendrocytes into mature cells. Antibody
blockade of LINGO-1 has shown promise in an animal
model of MS [51]. Neurotrophins are protein factors pro-
duced by CNS cells that support neuronal growth, survival
and differentiation [52]. In MS, secretion of the neuro-
trophin brain-derived neurotrophic factor (BDNF) is low
and dysregulated [53] and BDNF is therefore also being
considered as a therapeutic target.
Conclusion
Current MS therapeutics are moderately effective for mod-
ifying disease during its relapsing-remitting phase. There
are a number of oral and parenteral agents that target
inflammation in development and several are likely to be
approved for treatment of RRMS within the next few years.
These therapies will likely more effectively control RRMS
but will also carry greater known and, as yet, unknown
safety risks. These risks and benefits will have to be
weighed carefully against the efficacy and proven safety of
the IFNs and GA. Furthermore, none of the anti-inflam-
matory therapies currently in late stage of development
are likely to benefit patients with SPMS and PPMS. Devel-
opment of effective neuroprotective and neurorestorative
therapies are needed in order to benefit patients with pro-
gressive MS.
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